Advanced search
Publication Cover
Modern Rheumatology Volume 28, 2018 - Issue 4
Journal homepage
578
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Changes in serum interleukin-6 levels as possible predictor of efficacy of tocilizumab treatment in rheumatoid arthritis

Motohiko AizuDivision of Rheumatology, Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan; ;Saiseikai Kanazawa Hospital, Kanazawa, Japan;
,
Ichiro MizushimaDivision of Rheumatology, Department of Internal Medicine, Kanazawa University Hospital, Kanazawa, Japan;
,
Satoshi NakazakiKanazawa Jouhoku Hospital, Kanazawa, Japan;
,
Akikatsu NakashimaIshikawa Prefectural Central Hospital, Kanazawa, Japan;
,
Takashi KatoIshikawa Prefectural Central Hospital, Kanazawa, Japan;
,
Takashi MurayamaKanazawa Jouhoku Hospital, Kanazawa, Japan;
,
Shinichi KatoKanazawa Jouhoku Hospital, Kanazawa, Japan;
,
Yasuo KatsukiYawata Medical Center, Komatsu, Japan;
,
Kunihiro OganeIshikawa Prefectural Central Hospital, Kanazawa, Japan;
,
Hiroshi FujiiDivision of Rheumatology, Department of Internal Medicine, Kanazawa University Hospital, Kanazawa, Japan;
,
Kazunori YamadaDivision of Rheumatology, Department of Internal Medicine, Kanazawa University Hospital, Kanazawa, Japan;
,
Hideki NomuraDepartment of General Internal Medicine, Kanazawa University Hospital, Kanazawa, Japan;
,
Akihiro YachieDepartment of Pediatrics, Kanazawa University Graduate School of Medicine, Kanazawa, Japan;
,
Masakazu YamagishiDivision of Cardiology, Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
&
Mitsuhiro KawanoDivision of Rheumatology, Department of Internal Medicine, Kanazawa University Hospital, Kanazawa, Japan; Correspondence[email protected] [email protected]
 show all
Pages 592-598 | Received 10 May 2017, Accepted 17 Aug 2017, Published online: 12 Sep 2017

References

  • Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014;2:288–94.
  • Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878–88.
  • Kang S, Tanaka T, Kishimoto T. Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol. 2015;27:21–9.
  • Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.
  • Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12–19.
  • Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72:43–50.
  • Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients–REACTION 52-week study. Rheumatology (Oxford). 2011;50:1908–15.
  • Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T, et al. significance in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:3959–64.
  • Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, et al. Drug free Remission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol. 2014;24:17–25.
  • Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol. 2013;40:100–1.
  • Uno K, Yoshizaki K, Iwahashi M, Yamana J, Yamana S, Tanigawa M, et al. Pretreatment prediction of individual rheumatoid arthritis patients’ response to anti-cytokine therapy using serum cytokine/chemokine/soluble receptor biomarkers. PLoS One. 2015;15:10.
  • Lee SJ, Park W, Park SH, Shim SC, Baek HJ, Yoo DH, et al. Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients. J Immunol Res. 2015;2015:487230.
  • Wang J, Devenport J, Low JM, Yu D, Hitraya E. Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:882–5.
  • Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol. 2009;19:507–12.
  • Kasama T, Isojima S, Umemura M, Tsukamoto H, Tokunaga T, Furuya H, et al. Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis. Rheumatol Int. 2014;34:429–33.
  • Nishimoto N. Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol. 2006;18:277–81.
  • Kaneko Y, Atsumi T, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52 week results from a prospective, randomized, controlled study (SURPRISE STUDY). Ann Rheum Dis. 2016;75:1917–23.
  • Sugiura F, Kojima T, Oguchi T, Urata S, Yuzawa Y, Sakakibara A, et al. A case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis after a single infusion of tocilizumab. Mod Rheumatol. 2009;19:199–203.
  • De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–95.
  • Lang VR, Englbrecht M, Rech J, Nüsslein H, Manger K, Schuch F, et al. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford). 2012;51:852–7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.